High Free Cash Flow Stocks
BMY is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
BRISTOL-MYERS SQUIBB CO (BMY) Stock Price & Overview
NYSE:BMY • US1101221083
Current stock price
60.17 USD
+1.21 (+2.05%)
At close:
60.25 USD
+0.08 (+0.13%)
After Hours:
The current stock price of BMY is 60.17 USD. Today BMY is up by 2.05%. In the past month the price increased by 3.55%. In the past year, price increased by 22.22%.
BMY Key Statistics
52-Week Range42.52 - 62.8864
Current BMY stock price positioned within its 52-week range.
1-Month Range56.45 - 62.225
Current BMY stock price positioned within its 1-month range.
- Market Cap
- 122.851B
- P/E
- 9.78
- Fwd P/E
- 9.50
- EPS (TTM)
- 6.15
- Dividend Yield
- 4.24%
BMY Stock Performance
Today
+2.05%
1 Week
+2.64%
1 Month
+3.55%
3 Months
+8.89%
Longer-term
6 Months +37.91%
1 Year +22.22%
2 Years +36.94%
3 Years -9.88%
5 Years -3.60%
10 Years -16.64%
BMY Stock Chart
BMY Stock Screens
BMY currently appears in the following ChartMill screener lists.
BMY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BMY. When comparing the yearly performance of all stocks, BMY turns out to be only a medium performer in the overall market: it outperformed 62.81% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BMY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMY. BMY has an excellent profitability rating, but there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BMY Earnings
On February 5, 2026 BMY reported an EPS of 1.26 and a revenue of 12.50B. The company beat EPS expectations (11.85% surprise) and beat revenue expectations (0.79% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 5, 2026
PeriodQ4 / 2025
EPS Reported$1.26
Revenue Reported12.502B
EPS Surprise 11.85%
Revenue Surprise 0.79%
BMY Forecast & Estimates
36 analysts have analysed BMY and the average price target is 62.9 USD. This implies a price increase of 4.53% is expected in the next year compared to the current price of 60.17.
For the next year, analysts expect an EPS growth of 2.96% and a revenue growth -1.85% for BMY
Analysts
Analysts70.56
Price Target62.9 (4.54%)
EPS Next Y2.96%
Revenue Next Year-1.85%
BMY Groups
Sector & Classification
Sector
Health Care Sub-Industry
Pharmaceuticals BMY Financial Highlights
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 6.15. The EPS increased by 439.47% compared to the year before.
Income Statements
Revenue(TTM)48.19B
Net Income(TTM)7.05B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.64% | ||
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| Debt/Equity | 2.33 |
Chartmill High Growth Momentum
EPS Q2Q%-24.55%
Sales Q2Q%1.3%
EPS 1Y (TTM)439.47%
Revenue 1Y (TTM)-0.22%
BMY Ownership
Ownership
Inst Owners83.83%
Shares2.04B
Float2.04B
Ins Owners0.03%
Short Float %1.54%
Short Ratio2.37
BMY Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.51 | 854.108B | ||
| JNJ | JOHNSON & JOHNSON | 18.46 | 564.915B | ||
| MRK | MERCK & CO. INC. | 23.38 | 285.462B | ||
| PFE | PFIZER INC | 9.22 | 154.837B | ||
| ZTS | ZOETIS INC | 17.3 | 50.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.68 | 27.966B | ||
| VTRS | VIATRIS INC | 5.89 | 16.314B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.081B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.929B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.07 | 4.676B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BMY
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
IPO: 1980-03-17
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 32500
Phone: 13026587581
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What does BRISTOL-MYERS SQUIBB CO do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the current price of BMY stock?
The current stock price of BMY is 60.17 USD. The price increased by 2.05% in the last trading session.
Does BRISTOL-MYERS SQUIBB CO pay dividends?
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 4.24%. The yearly dividend amount is currently 2.51.
What is the ChartMill rating of BRISTOL-MYERS SQUIBB CO stock?
BMY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is BRISTOL-MYERS SQUIBB CO (BMY) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BMY.
Can you provide the ownership details for BMY stock?
You can find the ownership structure of BRISTOL-MYERS SQUIBB CO (BMY) on the Ownership tab.
What is the outstanding short interest for BRISTOL-MYERS SQUIBB CO?
The outstanding short interest for BRISTOL-MYERS SQUIBB CO (BMY) is 1.54% of its float.